Back to News
Market Impact: 0.4
Argenx's Celiac Disease Phase 2 Study Meets Primary Endpoint; Discontinues Sjögren's UNITY Trial
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
argenx reported positive Phase 2 results for FB102 in celiac disease, while separately announcing it will discontinue the Phase 3 UNITY study of efgartigimod in Sjögren's disease. The article gives no numerical trial results or explanation for ending the study, leaving the clinical update mixed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
ARGX0.10
More News
- Why is argenx stock rallying today?
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Rising fuel costs slashed Delta’s profit outlook despite strong demand
- ‘I drive a Tesla’: After Elon Musk said he’d lose his job, Delta CEO Ed Bastian says there’s ‘no tit for tat’ as airline unveils earnings miss
- Why is the Chinese stock market missing the AI rally
- OpenAI's revenue scare, Delta earnings, what investors think of a Starbucks-Chipotle deal and more in Morning Squawk